Isolated central nervous system progression on Crizotinib: An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

Stephen G. Chun, Kevin S. Choe, Puneeth Iyengar, John S. Yordy, Robert D. Timmerman

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Advanced non-small lung cancer (NS CLC) remains almost uniformly lethal with marginal long-term survival despite efforts to target specific oncogenic addiction pathways that may drive these tumors with small molecularly targeted agents and biologics. The EML4-ALK fusion gene encodes a chimeric tyrosine kinase that activates the Ras signaling pathway, and this fusion protein is found in approximately 5% of NS CLC. Targeting EML4-ALK with Crizotinib in this subset of NS CLC has documented therapeutic efficacy, but the vast majority of patients eventually develop recurrent disease that is often refractory to further treatments. We present the clinicopathologic features of three patients with metastatic NS CLC harboring the EML4-ALK translocation that developed isolated central nervous system (CNS ) metastases in the presence of good disease control elsewhere in the body. These cases suggest a differential response of NS CLC to Crizotinib in the brain in comparison to other sites of disease, and are consistent with a previous report of poor CNS penetration of Crizotinib. Results of ongoing clinical trials will clarify whether the CNS is a major sanctuary site for EML4-ALK positive NS CLC being treated with Crizotinib. While understanding molecular mechanisms of resistance is critical to overcome therapeutic resistance, understanding physiologic mechanisms of resistance through analyzing anatomic patterns of failure may be equally crucial to improve long-term survival for patients with EML4-ALK translocation positive NSCLC.

Original languageEnglish (US)
Pages (from-to)1376-1383
Number of pages8
JournalCancer Biology and Therapy
Volume13
Issue number14
DOIs
StatePublished - Dec 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Central Nervous System
Survival
Gene Fusion
Biological Factors
Protein-Tyrosine Kinases
Lung Neoplasms
Therapeutics
Clinical Trials
Neoplasm Metastasis
crizotinib
Brain
Neoplasms
Proteins

Keywords

  • Anaplastic lymphoma kinase (ALK)
  • Brain metastasis
  • Crizotinib
  • Non-small cell lung cancer
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Isolated central nervous system progression on Crizotinib : An Achilles heel of non-small cell lung cancer with EML4-ALK translocation? / Chun, Stephen G.; Choe, Kevin S.; Iyengar, Puneeth; Yordy, John S.; Timmerman, Robert D.

In: Cancer Biology and Therapy, Vol. 13, No. 14, 12.2012, p. 1376-1383.

Research output: Contribution to journalArticle

@article{f31487e4c70c43f5afe7f4286e7b64aa,
title = "Isolated central nervous system progression on Crizotinib: An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?",
abstract = "Advanced non-small lung cancer (NS CLC) remains almost uniformly lethal with marginal long-term survival despite efforts to target specific oncogenic addiction pathways that may drive these tumors with small molecularly targeted agents and biologics. The EML4-ALK fusion gene encodes a chimeric tyrosine kinase that activates the Ras signaling pathway, and this fusion protein is found in approximately 5{\%} of NS CLC. Targeting EML4-ALK with Crizotinib in this subset of NS CLC has documented therapeutic efficacy, but the vast majority of patients eventually develop recurrent disease that is often refractory to further treatments. We present the clinicopathologic features of three patients with metastatic NS CLC harboring the EML4-ALK translocation that developed isolated central nervous system (CNS ) metastases in the presence of good disease control elsewhere in the body. These cases suggest a differential response of NS CLC to Crizotinib in the brain in comparison to other sites of disease, and are consistent with a previous report of poor CNS penetration of Crizotinib. Results of ongoing clinical trials will clarify whether the CNS is a major sanctuary site for EML4-ALK positive NS CLC being treated with Crizotinib. While understanding molecular mechanisms of resistance is critical to overcome therapeutic resistance, understanding physiologic mechanisms of resistance through analyzing anatomic patterns of failure may be equally crucial to improve long-term survival for patients with EML4-ALK translocation positive NSCLC.",
keywords = "Anaplastic lymphoma kinase (ALK), Brain metastasis, Crizotinib, Non-small cell lung cancer, Stereotactic radiosurgery",
author = "Chun, {Stephen G.} and Choe, {Kevin S.} and Puneeth Iyengar and Yordy, {John S.} and Timmerman, {Robert D.}",
year = "2012",
month = "12",
doi = "10.4161/cbt.22255",
language = "English (US)",
volume = "13",
pages = "1376--1383",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "14",

}

TY - JOUR

T1 - Isolated central nervous system progression on Crizotinib

T2 - An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

AU - Chun, Stephen G.

AU - Choe, Kevin S.

AU - Iyengar, Puneeth

AU - Yordy, John S.

AU - Timmerman, Robert D.

PY - 2012/12

Y1 - 2012/12

N2 - Advanced non-small lung cancer (NS CLC) remains almost uniformly lethal with marginal long-term survival despite efforts to target specific oncogenic addiction pathways that may drive these tumors with small molecularly targeted agents and biologics. The EML4-ALK fusion gene encodes a chimeric tyrosine kinase that activates the Ras signaling pathway, and this fusion protein is found in approximately 5% of NS CLC. Targeting EML4-ALK with Crizotinib in this subset of NS CLC has documented therapeutic efficacy, but the vast majority of patients eventually develop recurrent disease that is often refractory to further treatments. We present the clinicopathologic features of three patients with metastatic NS CLC harboring the EML4-ALK translocation that developed isolated central nervous system (CNS ) metastases in the presence of good disease control elsewhere in the body. These cases suggest a differential response of NS CLC to Crizotinib in the brain in comparison to other sites of disease, and are consistent with a previous report of poor CNS penetration of Crizotinib. Results of ongoing clinical trials will clarify whether the CNS is a major sanctuary site for EML4-ALK positive NS CLC being treated with Crizotinib. While understanding molecular mechanisms of resistance is critical to overcome therapeutic resistance, understanding physiologic mechanisms of resistance through analyzing anatomic patterns of failure may be equally crucial to improve long-term survival for patients with EML4-ALK translocation positive NSCLC.

AB - Advanced non-small lung cancer (NS CLC) remains almost uniformly lethal with marginal long-term survival despite efforts to target specific oncogenic addiction pathways that may drive these tumors with small molecularly targeted agents and biologics. The EML4-ALK fusion gene encodes a chimeric tyrosine kinase that activates the Ras signaling pathway, and this fusion protein is found in approximately 5% of NS CLC. Targeting EML4-ALK with Crizotinib in this subset of NS CLC has documented therapeutic efficacy, but the vast majority of patients eventually develop recurrent disease that is often refractory to further treatments. We present the clinicopathologic features of three patients with metastatic NS CLC harboring the EML4-ALK translocation that developed isolated central nervous system (CNS ) metastases in the presence of good disease control elsewhere in the body. These cases suggest a differential response of NS CLC to Crizotinib in the brain in comparison to other sites of disease, and are consistent with a previous report of poor CNS penetration of Crizotinib. Results of ongoing clinical trials will clarify whether the CNS is a major sanctuary site for EML4-ALK positive NS CLC being treated with Crizotinib. While understanding molecular mechanisms of resistance is critical to overcome therapeutic resistance, understanding physiologic mechanisms of resistance through analyzing anatomic patterns of failure may be equally crucial to improve long-term survival for patients with EML4-ALK translocation positive NSCLC.

KW - Anaplastic lymphoma kinase (ALK)

KW - Brain metastasis

KW - Crizotinib

KW - Non-small cell lung cancer

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84870725524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870725524&partnerID=8YFLogxK

U2 - 10.4161/cbt.22255

DO - 10.4161/cbt.22255

M3 - Article

C2 - 22986231

AN - SCOPUS:84870725524

VL - 13

SP - 1376

EP - 1383

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 14

ER -